MET and neoplasm: Cabozantinib, as a multitargeted receptor tyrosine kinase (RTK) inhibitor, acts upon Mesenchymal Epithelial Transition Factor (MET), VEGFR, and AXL receptor tyrosine kinase (AXL), thereby hindering tumor cell growth and angiogenesis while concurrently modulating the tumor microenvironment [16].